Brind.

China's volume-based procurement policies are impacting pharmaceutical companies like Incepta and Envista.

1 report, 1 independent Updated Aug 15

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Incepta Pharmaceuticals China

Keep exploring

The entities involved

Incepta Pharmaceuticals
incepta
- Tilray Brands, Inc.'s stock change lagged the S&P 500 gain on August 28, 2025, while the company holds a Zacks Rank of #3.Sun 03:24
- Precision BioSciences and Incepta Pharmaceuticals were noted as belonging to a specified industry in August 2025.Sat 20:39
China
cultural region, ancient civilization, and nation in East Asia; mostly refers to the People's Republic of China in political situation and rarely refers to the Republic of China
- The European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Mon 17:49
- The Middle Corridor, linking Central Asia and Europe, is gaining significance in regional trade and energy routes.Mon 17:06

Coverage

Newest first; wire copies grouped

Aug 15ZacksZacks Industry Outlook Highlights Envista, BioLife Solutions, InfuSystems and MariMed Chicago, IL – August 15, 2025 – Today, Zacks Equity Research discusses Envista Holdings NVST, BioLife Solutions B